第2相試験で、脳内圧の有意な低下と毎月の頭痛の軽減が確認された Phase two trial saw significant reduction in pressure in the brain and monthly headaches
2023-03-13 バーミンガム大学
<関連情報>
- https://www.birmingham.ac.uk/news/2023/new-drug-to-lower-brain-pressure-could-treat-blinding-iih-headaches-trial-finds
- https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awad003/7065075?login=false
特発性頭蓋内圧亢進症に対するGLP-1RA exenatideの効果:無作為化臨床試験 The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
James L Mitchell, Hannah S Lyons, Jessica K Walker, Andreas Yiangou, Olivia Grech, Zerin Alimajstorovic, Nigel H Greig, Yazhou Li, Georgios Tsermoulas, Kristian Brock,Susan P Mollan, Alexandra J Sinclair
Brain Published:13 March 2023
DOI:https://doi.org/10.1093/brain/awad003
Abstract
Therapeutics to reduce intracranial pressure are an unmet need. Preclinical data have demonstrated a novel strategy to lower intracranial pressure using glucagon-like peptide-1 (GLP-1) receptor signalling.
Here, we translate these findings into patients by conducting a randomized, placebo-controlled, double-blind trial to assess the effect of exenatide, a GLP-1 receptor agonist, on intracranial pressure in idiopathic intracranial hypertension. Telemetric intracranial pressure catheters enabled long-term intracranial pressure monitoring. The trial enrolled adult women with active idiopathic intracranial hypertension (intracranial pressure >25 cmCSF and papilloedema) who receive subcutaneous exenatide or placebo. The three primary outcome measures were intracranial pressure at 2.5 h, 24 h and 12 weeks and alpha set a priori at less than 0.1.
Among the 16 women recruited, 15 completed the study (mean age 28 ± 9, body mass index 38.1 ± 6.2 kg/m2, intracranial pressure 30.6 ± 5.1 cmCSF). Exenatide significantly and meaningfully lowered intracranial pressure at 2.5 h -5.7 ± 2.9 cmCSF (P = 0.048); 24 h -6.4 ± 2.9 cmCSF (P = 0.030); and 12 weeks -5.6 ± 3.0 cmCSF (P = 0.058). No serious safety signals were noted.
These data provide confidence to proceed to a phase 3 trial in idiopathic intracranial hypertension and highlight the potential to utilize GLP-1 receptor agonist in other conditions characterized by raised intracranial pressure.
